VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q43159869  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010713.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q43159869‏
024 ‎‡a  0000-0001-7965-7512‏ ‎‡2  orcid‏
024 ‎‡a  26648725100‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q43159869‏
100 0 ‎‡a  María Jara-acevedo‏ ‎‡9  ast‏ ‎‡9  es‏ ‎‡9  sl‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  María Jara-acevedo‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  María Jara-acevedo‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.‏
670 ‎‡a  Author's Analysis of gene variants in the GASH/Sal model of epilepsy‏
670 ‎‡a  Author's Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas‏
670 ‎‡a  Author's CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis‏
670 ‎‡a  Author's Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis‏
670 ‎‡a  Author's Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.‏
670 ‎‡a  Author's Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.‏
670 ‎‡a  Author's CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults.‏
670 ‎‡a  Author's Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis‏
670 ‎‡a  Author's Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications‏
670 ‎‡a  Author's Evaluation of the WHO criteria for the classification of patients with mastocytosis.‏
670 ‎‡a  Author's Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count‏
670 ‎‡a  Author's Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool‏
670 ‎‡a  Author's Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis‏
670 ‎‡a  Author's Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis‏
670 ‎‡a  Author's Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations‏
670 ‎‡a  Author's Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.‏
670 ‎‡a  Author's Increased frequency‏
670 ‎‡a  Author's Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach‏
670 ‎‡a  Author's Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression‏
670 ‎‡a  Author's Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis‏
670 ‎‡a  Author's KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis‏
670 ‎‡a  Author's KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients‏
670 ‎‡a  Author's Mast cell-related disorders presenting with Kounis syndrome‏
670 ‎‡a  Author's Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.‏
670 ‎‡a  Author's Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.‏
670 ‎‡a  Author's Nonaggressive systemic mastocytosis‏
670 ‎‡a  Author's Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.‏
670 ‎‡a  Author's Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality‏
670 ‎‡a  Author's Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.‏
670 ‎‡a  Author's Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome‏
670 ‎‡a  Author's Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis.‏
670 ‎‡a  Author's The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis‏
670 ‎‡a  Author's Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms‏
909 ‎‡a  (orcid) 0000000179657512‏ ‎‡9  1‏
909 ‎‡a  (scopus) 26648725100‏ ‎‡9  1‏
919 ‎‡a  clinicalbiologicalandmolecularcharacteristicsofclonalmastcelldisorderspresentingwithsystemicmastcellactivationsymptoms‏ ‎‡A  Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.‏ ‎‡9  1‏
919 ‎‡a  indolentsystemicmastocytosiswithoutskininvolvementvsisolatedbonemarrowmastocytosis‏ ‎‡A  Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis‏ ‎‡9  1‏
919 ‎‡a  immunophenotypeofmastcellsanditsutilityinthediagnosticworkupofsystemicmastocytosis‏ ‎‡A  The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis‏ ‎‡9  1‏
919 ‎‡a  mastcellrelateddisorderspresentingwithkounissyndrome‏ ‎‡A  Mast cell-related disorders presenting with Kounis syndrome‏ ‎‡9  1‏
919 ‎‡a  immunophenotypinginsystemicmastocytosisdiagnosiscd25positivealoneismoreinformativethanthecd25andorcd2whocriterion‏ ‎‡A  Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.‏ ‎‡9  1‏
919 ‎‡a  nonaggressivesystemicmastocytosissmwithoutskinlesionsassociatedwithinsectinducedanaphylaxisshowsuniquefeaturesversusotherindolentsm‏ ‎‡A  Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.‏ ‎‡9  1‏
919 ‎‡a  phenotypicprofileofexpandednkcellsinchroniclymphoproliferativedisordersasurrogatemarkerfornkcellclonality‏ ‎‡A  Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality‏ ‎‡9  1‏
919 ‎‡a  nonaggressivesystemicmastocytosis‏ ‎‡A  Nonaggressive systemic mastocytosis‏ ‎‡9  1‏
919 ‎‡a  serumtryptasemonitoringinindolentsystemicmastocytosisassociationwithdiseasefeaturesandpatientoutcome‏ ‎‡A  Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome‏ ‎‡9  1‏
919 ‎‡a  validationoftheremascoreforpredictingmastcellclonalityandsystemicmastocytosisinpatientswithsystemicmastcellactivationsymptoms‏ ‎‡A  Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms‏ ‎‡9  1‏
919 ‎‡a  mastcellsfromdifferentmolecularandprognosticsubtypesofsystemicmastocytosisdisplaydistinctimmunophenotypes‏ ‎‡A  Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.‏ ‎‡9  1‏
919 ‎‡a  kitmutationinmastcellsandotherbonemarrowhematopoieticcelllineagesinsystemicmastcelldisordersaprospectivestudyofthespanishnetworkonmastocytosisremainaseriesof113patients‏ ‎‡A  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients‏ ‎‡9  1‏
919 ‎‡a  increasedil6plasmalevelsinindolentsystemicmastocytosispatientsareassociatedwithhighriskofdiseaseprogression‏ ‎‡A  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression‏ ‎‡9  1‏
919 ‎‡a  geneexpressionprofileofhighlypurifiedbonemarrowmastcellsinsystemicmastocytosis‏ ‎‡A  Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis‏ ‎‡9  1‏
919 ‎‡a  evaluationofthewhocriteriafortheclassificationofpatientswithmastocytosis‏ ‎‡A  Evaluation of the WHO criteria for the classification of patients with mastocytosis.‏ ‎‡9  1‏
919 ‎‡a  immunophenotypicalterationsofbonemarrowmyeloidcellcompartmentsinmultiplemyelomapatientspredictformyelodysplasiaassociatedcytogeneticalterations‏ ‎‡A  Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations‏ ‎‡9  1‏
919 ‎‡a  flowcytometrycriteriaforsystemicmastocytosisbonemarrowmastcellcountsdonotalwayscount‏ ‎‡A  Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count‏ ‎‡9  1‏
919 ‎‡a  detectionofthekitd816vmutationinperipheralbloodofsystemicmastocytosisdiagnosticimplications‏ ‎‡A  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications‏ ‎‡9  1‏
919 ‎‡a  completeresponseafterimatinibmesylatetherapyinapatientwithwelldifferentiatedsystemicmastocytosis‏ ‎‡A  Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis‏ ‎‡9  1‏
919 ‎‡a  analysisofgenevariantsinthegashsalmodelofepilepsy‏ ‎‡A  Analysis of gene variants in the GASH/Sal model of epilepsy‏ ‎‡9  1‏
919 ‎‡a  associationbetweenmutationofthenf2geneandmonosomy22inmenopausalwomenwithsporadicmeningiomas‏ ‎‡A  Association between mutation of the NF2 gene and monosomy 22 in menopausal women with sporadic meningiomas‏ ‎‡9  1‏
919 ‎‡a  cellcycledistributionofdifferentcellcompartmentsinnormalversusreactivebonemarrowaframeofreferenceforthestudyofdysplastichematopoiesis‏ ‎‡A  Cell-cycle distribution of different cell compartments in normal versus reactive bone marrow: a frame of reference for the study of dysplastic hematopoiesis‏ ‎‡9  1‏
919 ‎‡a  clllikeblymphocytesaresystematicallypresentatverylownumbersinperipheralbloodofhealthyadults‏ ‎‡A  CLL-like B-lymphocytes are systematically present at very low numbers in peripheral blood of healthy adults.‏ ‎‡9  1‏
919 ‎‡a  clinicalimmunophenotypicandmolecularcharacteristicsofwelldifferentiatedsystemicmastocytosis‏ ‎‡A  Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.‏ ‎‡9  1‏
919 ‎‡a  somaticd816vkitmutationinacaseofadultonsetfamilialmastocytosis‏ ‎‡A  Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis.‏ ‎‡9  1‏
919 ‎‡a  prognosisinadultindolentsystemicmastocytosisalongtermstudyofthespanishnetworkonmastocytosisinaseriesof145patients‏ ‎‡A  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.‏ ‎‡9  1‏
919 ‎‡a  newlydiagnosedadultamlandmpalpatientsfrequentlyshowclonalresidualhematopoiesis‏ ‎‡A  Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.‏ ‎‡9  1‏
919 ‎‡a  kitmutationinmastcellsandotherbonemarrowhematopoieticcelllineagesinsystemicmastcelldisordersaprospectivestudyofthespanishnetworkonmastocytosis‏ ‎‡A  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis‏ ‎‡9  1‏
919 ‎‡a  increasedfrequency12ofcirculatingchroniclymphocyticleukemialikebcellclonesinhealthysubjectsusingahighlysensitivemulticolorflowcytometryapproach‏ ‎‡A  Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach‏ ‎‡9  1‏
919 ‎‡a  increasedfrequency‏ ‎‡A  Increased frequency‏ ‎‡9  1‏
919 ‎‡a  frequencyandprognosticimpactofkitandothergeneticvariantsinindolentsystemicmastocytosis‏ ‎‡A  Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis‏ ‎‡9  1‏
919 ‎‡a  flowcytometryinmastocytosisutilityasadiagnosticandprognostictool‏ ‎‡A  Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool‏ ‎‡9  1‏
919 ‎‡a  cd30expressionbybonemarrowmastcellsfromdifferentdiagnosticvariantsofsystemicmastocytosis‏ ‎‡A  CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis‏ ‎‡9  1‏
919 ‎‡a  immatureimmunophenotypeofbonemarrowmastcellspredictsformultilineaged816vkitmutationinsystemicmastocytosis‏ ‎‡A  An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000103728644‏
996 ‎‡2  LC|no2009095533‏
996 ‎‡2  NII|DA12282293‏
996 ‎‡2  SUDOC|10220828X‏
996 ‎‡2  BIBSYS|4083934‏
996 ‎‡2  ISNI|0000000029924750‏
996 ‎‡2  BNE|XX4616452‏
996 ‎‡2  ISNI|0000000453813806‏
996 ‎‡2  BNE|XX4420809‏
996 ‎‡2  BNE|XX820448‏
996 ‎‡2  BNF|16616608‏
996 ‎‡2  SUDOC|160950295‏
996 ‎‡2  BNCHL|10000000000000000106161‏
996 ‎‡2  CAOONL|ncf10705551‏
996 ‎‡2  DNB|1047925818‏
996 ‎‡2  LC|nb2015016985‏
996 ‎‡2  LC|n 92027670‏
996 ‎‡2  BNCHL|10000000000000000046374‏
996 ‎‡2  LC|no2003109182‏
996 ‎‡2  ISNI|0000000050508655‏
996 ‎‡2  NSK|000440880‏
996 ‎‡2  BNE|XX6440312‏
996 ‎‡2  LC|n 2008064648‏
996 ‎‡2  BNCHL|10000000000000000015285‏
996 ‎‡2  ISNI|0000000062423317‏
996 ‎‡2  LC|ns2013003521‏
996 ‎‡2  DNB|1023133385‏
996 ‎‡2  LC|n 93122972‏
996 ‎‡2  ISNI|0000000039701438‏
996 ‎‡2  LC|no2021149273‏
996 ‎‡2  BNCHL|10000000000000000027049‏
996 ‎‡2  LC|n 92002989‏
996 ‎‡2  LC|n 2016003217‏
996 ‎‡2  BNE|XX1076965‏
996 ‎‡2  BNF|15098484‏
996 ‎‡2  SUDOC|165126213‏
996 ‎‡2  DNB|1056333227‏
996 ‎‡2  DNB|1015682561‏
996 ‎‡2  ISNI|0000000029534832‏
996 ‎‡2  LC|no2016061077‏
996 ‎‡2  LC|ns2011002408‏
996 ‎‡2  LC|ns2021003310‏
996 ‎‡2  LC|n 89660477‏
996 ‎‡2  ISNI|0000000004834791‏
996 ‎‡2  LC|nr2002039311‏
996 ‎‡2  DNB|104792675X‏
996 ‎‡2  DNB|1265409307‏
996 ‎‡2  DNB|170097404‏
996 ‎‡2  SUDOC|268371628‏
996 ‎‡2  ISNI|0000000420194084‏
996 ‎‡2  LC|n 2021013918‏
996 ‎‡2  NTA|242594921‏
996 ‎‡2  ISNI|0000000026674901‏
996 ‎‡2  LC|n 85198027‏
996 ‎‡2  DNB|105663572X‏
996 ‎‡2  LC|no2017022519‏
996 ‎‡2  LC|ns2012004460‏
996 ‎‡2  LC|ns2019003413‏
996 ‎‡2  LC|no2024135284‏
996 ‎‡2  DNB|1057434639‏
996 ‎‡2  ISNI|0000000053488637‏
996 ‎‡2  LC|n 86125055‏
996 ‎‡2  LC|n 2013062049‏
996 ‎‡2  PTBNP|2046‏
996 ‎‡2  ISNI|0000000109396206‏
996 ‎‡2  ISNI|0000000028703294‏
996 ‎‡2  SUDOC|144509385‏
996 ‎‡2  SUDOC|200909509‏
996 ‎‡2  NKC|pna2016916084‏
996 ‎‡2  ISNI|0000000032145117‏
996 ‎‡2  BNCHL|10000000000000000077815‏
996 ‎‡2  DNB|1214196624‏
996 ‎‡2  LC|ns2014005415‏
996 ‎‡2  DNB|129525235‏
996 ‎‡2  LC|n 90612783‏
996 ‎‡2  ISNI|0000000048466142‏
996 ‎‡2  NUKAT|n 2011141612‏
996 ‎‡2  NUKAT|n 2012151044‏
996 ‎‡2  BNCHL|10000000000000000856761‏
996 ‎‡2  LC|no2020149224‏
996 ‎‡2  ISNI|000000008158938X‏
996 ‎‡2  LC|n 87151550‏
996 ‎‡2  J9U|987007297857505171‏
996 ‎‡2  BIBSYS|90699588‏
996 ‎‡2  BNCHL|10000000000000000797423‏
996 ‎‡2  DNB|170364178‏
996 ‎‡2  BNE|XX5249399‏
996 ‎‡2  DNB|1192998006‏
996 ‎‡2  J9U|987007601406105171‏
996 ‎‡2  ISNI|0000000054688737‏
996 ‎‡2  BNCHL|10000000000000000856570‏
996 ‎‡2  J9U|987007511761905171‏
996 ‎‡2  LC|no2017053214‏
996 ‎‡2  DNB|1265409226‏
996 ‎‡2  BLBNB|000459114‏
996 ‎‡2  ISNI|0000000039726432‏
996 ‎‡2  DNB|1047925060‏
996 ‎‡2  ISNI|0000000384751209‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏